JP6764862B2 - 耐性細菌感染症の治療のための併用療法 - Google Patents
耐性細菌感染症の治療のための併用療法 Download PDFInfo
- Publication number
- JP6764862B2 JP6764862B2 JP2017526516A JP2017526516A JP6764862B2 JP 6764862 B2 JP6764862 B2 JP 6764862B2 JP 2017526516 A JP2017526516 A JP 2017526516A JP 2017526516 A JP2017526516 A JP 2017526516A JP 6764862 B2 JP6764862 B2 JP 6764862B2
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- sulbactam
- compound
- imipenem
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000035143 Bacterial infection Diseases 0.000 title claims description 127
- 208000022362 bacterial infectious disease Diseases 0.000 title claims description 126
- 238000011282 treatment Methods 0.000 title claims description 61
- 238000002648 combination therapy Methods 0.000 title description 2
- 150000003839 salts Chemical class 0.000 claims description 565
- FKENQMMABCRJMK-RITPCOANSA-N sulbactam Chemical compound O=S1(=O)C(C)(C)[C@H](C(O)=O)N2C(=O)C[C@H]21 FKENQMMABCRJMK-RITPCOANSA-N 0.000 claims description 321
- 229960005256 sulbactam Drugs 0.000 claims description 320
- WKDDRNSBRWANNC-UHFFFAOYSA-N Thienamycin Natural products C1C(SCCN)=C(C(O)=O)N2C(=O)C(C(O)C)C21 WKDDRNSBRWANNC-UHFFFAOYSA-N 0.000 claims description 108
- 229960002182 imipenem Drugs 0.000 claims description 108
- ZSKVGTPCRGIANV-ZXFLCMHBSA-N imipenem Chemical compound C1C(SCC\N=C\N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 ZSKVGTPCRGIANV-ZXFLCMHBSA-N 0.000 claims description 108
- 244000052769 pathogen Species 0.000 claims description 58
- 239000003781 beta lactamase inhibitor Substances 0.000 claims description 57
- 229940126813 beta-lactamase inhibitor Drugs 0.000 claims description 57
- 230000001717 pathogenic effect Effects 0.000 claims description 48
- DHSUYTOATWAVLW-WFVMDLQDSA-N cilastatin Chemical compound CC1(C)C[C@@H]1C(=O)N\C(=C/CCCCSC[C@H](N)C(O)=O)C(O)=O DHSUYTOATWAVLW-WFVMDLQDSA-N 0.000 claims description 44
- 229940126085 β‑Lactamase Inhibitor Drugs 0.000 claims description 44
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 claims description 37
- 229960000723 ampicillin Drugs 0.000 claims description 37
- 229960004912 cilastatin Drugs 0.000 claims description 33
- 239000003814 drug Substances 0.000 claims description 29
- 229960004682 cefoperazone Drugs 0.000 claims description 27
- GCFBRXLSHGKWDP-XCGNWRKASA-N cefoperazone Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC(O)=CC=1)C(=O)N[C@@H]1C(=O)N2C(C(O)=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 GCFBRXLSHGKWDP-XCGNWRKASA-N 0.000 claims description 27
- 241000588921 Enterobacteriaceae Species 0.000 claims description 26
- 239000003085 diluting agent Substances 0.000 claims description 21
- 229940079593 drug Drugs 0.000 claims description 20
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims description 19
- 241000589291 Acinetobacter Species 0.000 claims description 14
- 239000013066 combination product Substances 0.000 claims description 13
- 229940127555 combination product Drugs 0.000 claims description 13
- 241001453380 Burkholderia Species 0.000 claims description 11
- 239000003937 drug carrier Substances 0.000 claims description 10
- 159000000000 sodium salts Chemical class 0.000 claims description 3
- 229940125904 compound 1 Drugs 0.000 description 235
- 208000015181 infectious disease Diseases 0.000 description 106
- NCCJWSXETVVUHK-ZYSAIPPVSA-N (z)-7-[(2r)-2-amino-2-carboxyethyl]sulfanyl-2-[[(1s)-2,2-dimethylcyclopropanecarbonyl]amino]hept-2-enoic acid;(5r,6s)-3-[2-(aminomethylideneamino)ethylsulfanyl]-6-[(1r)-1-hydroxyethyl]-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid Chemical compound C1C(SCC\N=C/N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21.CC1(C)C[C@@H]1C(=O)N\C(=C/CCCCSC[C@H](N)C(O)=O)C(O)=O NCCJWSXETVVUHK-ZYSAIPPVSA-N 0.000 description 55
- 102000006635 beta-lactamase Human genes 0.000 description 51
- 238000000034 method Methods 0.000 description 50
- 239000000203 mixture Substances 0.000 description 48
- 241000588626 Acinetobacter baumannii Species 0.000 description 46
- 239000008194 pharmaceutical composition Substances 0.000 description 43
- 241000894006 Bacteria Species 0.000 description 37
- 150000001875 compounds Chemical class 0.000 description 37
- OPYGFNJSCUDTBT-PMLPCWDUSA-N sultamicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(=O)OCOC(=O)[C@H]2C(S(=O)(=O)[C@H]3N2C(C3)=O)(C)C)(C)C)=CC=CC=C1 OPYGFNJSCUDTBT-PMLPCWDUSA-N 0.000 description 32
- 241001465754 Metazoa Species 0.000 description 31
- 108020004256 Beta-lactamase Proteins 0.000 description 30
- 230000000694 effects Effects 0.000 description 26
- 239000000546 pharmaceutical excipient Substances 0.000 description 23
- 108090000204 Dipeptidase 1 Proteins 0.000 description 22
- 239000000047 product Substances 0.000 description 22
- 230000003115 biocidal effect Effects 0.000 description 20
- 238000009472 formulation Methods 0.000 description 18
- 230000001580 bacterial effect Effects 0.000 description 17
- WIKQLQXZUYAZQC-KYNIKAHCSA-N (2s,5r)-3,3-dimethyl-4,4,7-trioxo-4$l^{6}-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;(6r,7r)-7-[[(2r)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-(4-hydroxyphenyl)acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabic Chemical compound O=S1(=O)C(C)(C)[C@H](C(O)=O)N2C(=O)C[C@H]21.O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC(O)=CC=1)C(=O)N[C@@H]1C(=O)N2C(C(O)=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 WIKQLQXZUYAZQC-KYNIKAHCSA-N 0.000 description 16
- 241000282412 Homo Species 0.000 description 16
- 229960001326 sultamicillin Drugs 0.000 description 16
- 229940020930 unasyn Drugs 0.000 description 16
- 239000013543 active substance Substances 0.000 description 14
- 208000035473 Communicable disease Diseases 0.000 description 13
- 239000004480 active ingredient Substances 0.000 description 13
- 230000000844 anti-bacterial effect Effects 0.000 description 13
- 206010035664 Pneumonia Diseases 0.000 description 12
- 239000003242 anti bacterial agent Substances 0.000 description 12
- 201000010099 disease Diseases 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- -1 doxicylin Chemical compound 0.000 description 12
- 229960002260 meropenem Drugs 0.000 description 12
- DMJNNHOOLUXYBV-PQTSNVLCSA-N meropenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](C(=O)N(C)C)C1 DMJNNHOOLUXYBV-PQTSNVLCSA-N 0.000 description 12
- 230000036457 multidrug resistance Effects 0.000 description 11
- 229940027836 primaxin Drugs 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- 102000004190 Enzymes Human genes 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 10
- 239000002253 acid Substances 0.000 description 10
- 229940088710 antibiotic agent Drugs 0.000 description 10
- 208000019206 urinary tract infection Diseases 0.000 description 10
- 239000005414 inactive ingredient Substances 0.000 description 9
- 201000009906 Meningitis Diseases 0.000 description 8
- 206010028813 Nausea Diseases 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- 229960003907 linezolid Drugs 0.000 description 8
- TYZROVQLWOKYKF-ZDUSSCGKSA-N linezolid Chemical compound O=C1O[C@@H](CNC(=O)C)CN1C(C=C1F)=CC=C1N1CCOCC1 TYZROVQLWOKYKF-ZDUSSCGKSA-N 0.000 description 8
- 230000008693 nausea Effects 0.000 description 8
- 239000003381 stabilizer Substances 0.000 description 8
- 239000004094 surface-active agent Substances 0.000 description 8
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 7
- 238000001802 infusion Methods 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- YCIHPQHVWDULOY-FMZCEJRJSA-N (4s,4as,5as,6s,12ar)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide;hydrochloride Chemical compound Cl.C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O YCIHPQHVWDULOY-FMZCEJRJSA-N 0.000 description 6
- 229940121375 antifungal agent Drugs 0.000 description 6
- 239000000739 antihistaminic agent Substances 0.000 description 6
- 230000009977 dual effect Effects 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 238000001990 intravenous administration Methods 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 108010013639 Peptidoglycan Proteins 0.000 description 5
- 241000191967 Staphylococcus aureus Species 0.000 description 5
- 230000003110 anti-inflammatory effect Effects 0.000 description 5
- 239000006161 blood agar Substances 0.000 description 5
- 208000027096 gram-negative bacterial infections Diseases 0.000 description 5
- 239000012510 hollow fiber Substances 0.000 description 5
- 230000002195 synergetic effect Effects 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- ACQFJWSLWQLLIA-PLWQYUFKSA-N (1e,5s,8as,8br)-1-ethylidene-5-methoxy-2-oxo-5,6,7,8,8a,8b-hexahydroazeto[1,2-b]isoindole-4-carboxylic acid Chemical compound CO[C@H]1CCC[C@@H]2[C@@H]3C(=C\C)/C(=O)N3C(C(O)=O)=C12 ACQFJWSLWQLLIA-PLWQYUFKSA-N 0.000 description 4
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical class O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 description 4
- 108010013198 Daptomycin Proteins 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 108010015899 Glycopeptides Proteins 0.000 description 4
- 102000002068 Glycopeptides Human genes 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 108010034396 Streptogramins Proteins 0.000 description 4
- 208000031650 Surgical Wound Infection Diseases 0.000 description 4
- 108010059993 Vancomycin Proteins 0.000 description 4
- 206010048038 Wound infection Diseases 0.000 description 4
- 229940126575 aminoglycoside Drugs 0.000 description 4
- 239000003429 antifungal agent Substances 0.000 description 4
- 229940125715 antihistaminic agent Drugs 0.000 description 4
- 229960003405 ciprofloxacin Drugs 0.000 description 4
- DOAKLVKFURWEDJ-QCMAZARJSA-N daptomycin Chemical compound C([C@H]1C(=O)O[C@H](C)[C@@H](C(NCC(=O)N[C@@H](CCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@H](CO)C(=O)N[C@H](C(=O)N1)[C@H](C)CC(O)=O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CCCCCCCCC)C(=O)C1=CC=CC=C1N DOAKLVKFURWEDJ-QCMAZARJSA-N 0.000 description 4
- 229960005484 daptomycin Drugs 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 229940124307 fluoroquinolone Drugs 0.000 description 4
- 229960000308 fosfomycin Drugs 0.000 description 4
- YMDXZJFXQJVXBF-STHAYSLISA-N fosfomycin Chemical compound C[C@@H]1O[C@@H]1P(O)(O)=O YMDXZJFXQJVXBF-STHAYSLISA-N 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 239000003120 macrolide antibiotic agent Substances 0.000 description 4
- 229940041033 macrolides Drugs 0.000 description 4
- 150000004957 nitroimidazoles Chemical class 0.000 description 4
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- RFSWVJXWZXQOSW-ZDFSRXSCSA-M sodium;(5r,6z)-6-(6,8-dihydro-5h-imidazo[2,1-c][1,4]oxazin-2-ylmethylidene)-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate Chemical compound [Na+].C1COCC2=NC(/C=C3/C(=O)N4[C@@H]3SC=C4C(=O)[O-])=CN21 RFSWVJXWZXQOSW-ZDFSRXSCSA-M 0.000 description 4
- 229940041030 streptogramins Drugs 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- LPQZKKCYTLCDGQ-WEDXCCLWSA-N tazobactam Chemical compound C([C@]1(C)S([C@H]2N(C(C2)=O)[C@H]1C(O)=O)(=O)=O)N1C=CN=N1 LPQZKKCYTLCDGQ-WEDXCCLWSA-N 0.000 description 4
- 229960003865 tazobactam Drugs 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 229960000707 tobramycin Drugs 0.000 description 4
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 4
- 238000012384 transportation and delivery Methods 0.000 description 4
- 210000000689 upper leg Anatomy 0.000 description 4
- 229960003165 vancomycin Drugs 0.000 description 4
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 4
- MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 description 4
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 3
- MINDHVHHQZYEEK-UHFFFAOYSA-N (E)-(2S,3R,4R,5S)-5-[(2S,3S,4S,5S)-2,3-epoxy-5-hydroxy-4-methylhexyl]tetrahydro-3,4-dihydroxy-(beta)-methyl-2H-pyran-2-crotonic acid ester with 9-hydroxynonanoic acid Natural products CC(O)C(C)C1OC1CC1C(O)C(O)C(CC(C)=CC(=O)OCCCCCCCCC(O)=O)OC1 MINDHVHHQZYEEK-UHFFFAOYSA-N 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- 201000004384 Alopecia Diseases 0.000 description 3
- 208000006820 Arthralgia Diseases 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 3
- 206010011409 Cross infection Diseases 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 241000588914 Enterobacter Species 0.000 description 3
- 101000740462 Escherichia coli Beta-lactamase TEM Proteins 0.000 description 3
- 208000010201 Exanthema Diseases 0.000 description 3
- 206010019233 Headaches Diseases 0.000 description 3
- 241000588748 Klebsiella Species 0.000 description 3
- 108010004718 Lipoglycopeptides Proteins 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 206010040047 Sepsis Diseases 0.000 description 3
- 206010040844 Skin exfoliation Diseases 0.000 description 3
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 3
- 206010041349 Somnolence Diseases 0.000 description 3
- 208000005392 Spasm Diseases 0.000 description 3
- 206010042674 Swelling Diseases 0.000 description 3
- 208000025865 Ulcer Diseases 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 230000000845 anti-microbial effect Effects 0.000 description 3
- 229960002379 avibactam Drugs 0.000 description 3
- NDCUAPJVLWFHHB-UHNVWZDZSA-N avibactam Chemical compound C1N2[C@H](C(N)=O)CC[C@@]1([H])N(OS(O)(=O)=O)C2=O NDCUAPJVLWFHHB-UHNVWZDZSA-N 0.000 description 3
- 239000003782 beta lactam antibiotic agent Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000005252 bulbus oculi Anatomy 0.000 description 3
- 229960000956 coumarin Drugs 0.000 description 3
- 235000001671 coumarin Nutrition 0.000 description 3
- 208000002173 dizziness Diseases 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 229960003722 doxycycline Drugs 0.000 description 3
- 201000005884 exanthem Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 206010016256 fatigue Diseases 0.000 description 3
- 238000001640 fractional crystallisation Methods 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 208000024963 hair loss Diseases 0.000 description 3
- 230000003676 hair loss Effects 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 206010022437 insomnia Diseases 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000003843 mucus production Effects 0.000 description 3
- 229960003128 mupirocin Drugs 0.000 description 3
- 229930187697 mupirocin Natural products 0.000 description 3
- DDHVILIIHBIMQU-YJGQQKNPSA-L mupirocin calcium hydrate Chemical compound O.O.[Ca+2].C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1.C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1 DDHVILIIHBIMQU-YJGQQKNPSA-L 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 206010037844 rash Diseases 0.000 description 3
- 210000002345 respiratory system Anatomy 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 231100000397 ulcer Toxicity 0.000 description 3
- 230000008673 vomiting Effects 0.000 description 3
- 239000002132 β-lactam antibiotic Substances 0.000 description 3
- 229940124586 β-lactam antibiotics Drugs 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- KMEGBUCIGMEPME-LQYKFRDPSA-N (2s,5r,6r)-6-[[(2r)-2-amino-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;(1r,4s)-3,3-dimethyl-2,2,6-trioxo-2$l^{6}-thiabicyclo[3.2.0]heptane-4-carboxylic acid Chemical compound O=S1(=O)C(C)(C)[C@H](C(O)=O)C2C(=O)C[C@H]21.C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 KMEGBUCIGMEPME-LQYKFRDPSA-N 0.000 description 2
- SCVJRXQHFJXZFZ-KVQBGUIXSA-N 2-amino-9-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purine-6-thione Chemical compound C1=2NC(N)=NC(=S)C=2N=CN1[C@H]1C[C@H](O)[C@@H](CO)O1 SCVJRXQHFJXZFZ-KVQBGUIXSA-N 0.000 description 2
- FYZUENZXIZCLAZ-UHFFFAOYSA-N 2-methylhept-2-enoic acid Chemical compound CCCCC=C(C)C(O)=O FYZUENZXIZCLAZ-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- 208000034950 Acinetobacter Infections Diseases 0.000 description 2
- 208000029329 Acinetobacter infectious disease Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- 241000588923 Citrobacter Species 0.000 description 2
- 206010061977 Genital infection female Diseases 0.000 description 2
- 229930182566 Gentamicin Natural products 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- 208000036209 Intraabdominal Infections Diseases 0.000 description 2
- 241000588747 Klebsiella pneumoniae Species 0.000 description 2
- 208000007101 Muscle Cramp Diseases 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- 206010053159 Organ failure Diseases 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 241000588769 Proteus <enterobacteria> Species 0.000 description 2
- 208000032536 Pseudomonas Infections Diseases 0.000 description 2
- 206010057190 Respiratory tract infections Diseases 0.000 description 2
- 241000607142 Salmonella Species 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 241000607720 Serratia Species 0.000 description 2
- 241000607768 Shigella Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 2
- BISPBXFUKNXOQY-RITPCOANSA-N [(2s,5r)-2-carbamoyl-3-methyl-7-oxo-1,6-diazabicyclo[3.2.1]oct-3-en-6-yl] hydrogen sulfate Chemical compound NC(=O)[C@@H]1C(C)=C[C@H]2N(OS(O)(=O)=O)C(=O)N1C2 BISPBXFUKNXOQY-RITPCOANSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 241001148470 aerobic bacillus Species 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 230000001387 anti-histamine Effects 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 206010006451 bronchitis Diseases 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000003113 dilution method Methods 0.000 description 2
- 229960002518 gentamicin Drugs 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000012678 infectious agent Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- RBKMMJSQKNKNEV-RITPCOANSA-N penicillanic acid Chemical compound OC(=O)[C@H]1C(C)(C)S[C@@H]2CC(=O)N21 RBKMMJSQKNKNEV-RITPCOANSA-N 0.000 description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 2
- 238000012385 systemic delivery Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 150000003952 β-lactams Chemical class 0.000 description 2
- YBZQRYWKYBZZNT-SCSAIBSYSA-N (1s)-2,2-dimethylcyclopropane-1-carboxamide Chemical compound CC1(C)C[C@@H]1C(N)=O YBZQRYWKYBZZNT-SCSAIBSYSA-N 0.000 description 1
- AAWZDTNXLSGCEK-LNVDRNJUSA-N (3r,5r)-1,3,4,5-tetrahydroxycyclohexane-1-carboxylic acid Chemical class O[C@@H]1CC(O)(C(O)=O)C[C@@H](O)C1O AAWZDTNXLSGCEK-LNVDRNJUSA-N 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N (e)-2-hydroxybut-2-enedioic acid Chemical compound OC(=O)\C=C(\O)C(O)=O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- FFRUQSUMDFNBLG-UHFFFAOYSA-N 2-(2,4,5-trichlorophenoxy)ethyl 2,2,2-trichloroacetate Chemical compound ClC1=CC(Cl)=C(OCCOC(=O)C(Cl)(Cl)Cl)C=C1Cl FFRUQSUMDFNBLG-UHFFFAOYSA-N 0.000 description 1
- IVHKZCSZELZKSJ-UHFFFAOYSA-N 2-hydroxyethyl sulfonate Chemical compound OCCOS(=O)=O IVHKZCSZELZKSJ-UHFFFAOYSA-N 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- HVBSAKJJOYLTQU-UHFFFAOYSA-M 4-aminobenzenesulfonate Chemical compound NC1=CC=C(S([O-])(=O)=O)C=C1 HVBSAKJJOYLTQU-UHFFFAOYSA-M 0.000 description 1
- 206010056519 Abdominal infection Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010001076 Acute sinusitis Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 208000031729 Bacteremia Diseases 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 206010069747 Burkholderia mallei infection Diseases 0.000 description 1
- 206010069748 Burkholderia pseudomallei infection Diseases 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- 101100026178 Caenorhabditis elegans egl-3 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 108010078777 Colistin Proteins 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 102000015833 Cystatin Human genes 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical class C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 241000194032 Enterococcus faecalis Species 0.000 description 1
- 208000002633 Febrile Neutropenia Diseases 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 201000003641 Glanders Diseases 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 208000008745 Healthcare-Associated Pneumonia Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 229940123930 Lactamase inhibitor Drugs 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 206010024652 Liver abscess Diseases 0.000 description 1
- 208000032376 Lung infection Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010028780 Nasal ulcer Diseases 0.000 description 1
- 206010028885 Necrotising fasciitis Diseases 0.000 description 1
- 206010059482 Neutropenic infection Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 108010048233 Procalcitonin Proteins 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 208000019802 Sexually transmitted disease Diseases 0.000 description 1
- 206010041925 Staphylococcal infections Diseases 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 208000034784 Tularaemia Diseases 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 208000009470 Ventilator-Associated Pneumonia Diseases 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 229940043312 ampicillin / sulbactam Drugs 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- 125000003460 beta-lactamyl group Chemical group 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 208000037815 bloodstream infection Diseases 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 201000006824 bubonic plague Diseases 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- YZBQHRLRFGPBSL-RXMQYKEDSA-N carbapenem Chemical compound C1C=CN2C(=O)C[C@H]21 YZBQHRLRFGPBSL-RXMQYKEDSA-N 0.000 description 1
- 229940041011 carbapenems Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 201000004308 chancroid Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 239000012069 chiral reagent Substances 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- HZZVJAQRINQKSD-PBFISZAISA-N clavulanic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 description 1
- 229960003324 clavulanic acid Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 229960003346 colistin Drugs 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 108050004038 cystatin Proteins 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 150000008050 dialkyl sulfates Chemical class 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical class [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- NWOYIVRVSJDTLK-YSDBFZIDSA-L disodium;(2s,5r,6r)-6-[[(2r)-2-amino-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate;(1r,4s)-3,3-dimethyl-2,2,6-trioxo-2$l^{6}-thiabicyclo[3.2.0]heptane-4-carboxylate Chemical compound [Na+].[Na+].O=S1(=O)C(C)(C)[C@H](C([O-])=O)C2C(=O)C[C@H]21.C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C([O-])=O)(C)C)=CC=CC=C1 NWOYIVRVSJDTLK-YSDBFZIDSA-L 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940032049 enterococcus faecalis Drugs 0.000 description 1
- 238000006345 epimerization reaction Methods 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 208000020426 gonococcal urethritis Diseases 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229910052602 gypsum Inorganic materials 0.000 description 1
- 239000010440 gypsum Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000022760 infectious otitis media Diseases 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 229960003376 levofloxacin Drugs 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000008263 liquid aerosol Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 201000004015 melioidosis Diseases 0.000 description 1
- 238000010197 meta-analysis Methods 0.000 description 1
- 108060004734 metallo-beta-lactamase Proteins 0.000 description 1
- 102000020235 metallo-beta-lactamase Human genes 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical group CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- JORAUNFTUVJTNG-BSTBCYLQSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Chemical compound CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O JORAUNFTUVJTNG-BSTBCYLQSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- 201000007970 necrotizing fasciitis Diseases 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L persulfate group Chemical group S(=O)(=O)([O-])OOS(=O)(=O)[O-] JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical class OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 125000005547 pivalate group Chemical group 0.000 description 1
- XDJYMJULXQKGMM-UHFFFAOYSA-N polymyxin E1 Natural products CCC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O XDJYMJULXQKGMM-UHFFFAOYSA-N 0.000 description 1
- KNIWPHSUTGNZST-UHFFFAOYSA-N polymyxin E2 Natural products CC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O KNIWPHSUTGNZST-UHFFFAOYSA-N 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- CWCXERYKLSEGEZ-KDKHKZEGSA-N procalcitonin Chemical compound C([C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(O)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H]1NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@@H](N)CSSC1)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 CWCXERYKLSEGEZ-KDKHKZEGSA-N 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 230000010837 receptor-mediated endocytosis Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid Chemical class NS(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 238000012070 whole genome sequencing analysis Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
またはその医薬的に許容される塩と、スルバクタム:
またはその医薬的に許容される塩の組み合わせに関する。
またはその医薬的に許容される塩;
スルバクタム:
またはその医薬的に許容される塩;
イミペネム:
またはその医薬的に許容される塩;及び
シラスタチン:
またはその医薬的に許容される塩の組み合わせに関する。
またはその医薬的に許容される塩と、スルバクタムまたはその医薬的に許容される塩(以下、「二重組み合わせ」と呼ぶ)を含む、から本質的になる、またはからなる組み合わせを提供する。二重組み合わせは、薬剤耐性菌によって引き起こされる感染症を含む、限定されないが、アシネトバクター属、緑膿菌、腸内細菌科、及び/またはバークホルデリア属を含む病原菌によって引き起こされる細菌感染症の治療に有用である。
またはその医薬的に許容される塩;スルバクタムまたはその医薬的に許容される塩;イミペネムまたはその医薬的に許容される塩;及びシラスタチンまたはその医薬的に許容される塩を含む、から本質的になる、またはからなる組み合わせに関する。
またはその医薬的に許容される塩である。「スルバクタム」という用語は、本明細書で使用する場合、(2S,5R)−3,3−ジメチル−7−オキソ−4−チア−1−アザビシクロ[3.2.0]ヘプタン−2−カルボン酸4,4−ジオキシドを含有する商業的に関連する製剤も含み、そのナトリウム塩、例えば、スルバクタム、さらに、アンピシリンまたはセフォペラゾン、またはその塩を含有する組み合わせ製品は、「スルバクタム+アンピシリンまたはセフォペラゾン組み合わせ製品」とも本明細書で呼ばれる。誤解を避けるために、「スルバクタム」及び「スルバクタム+アンピシリンまたはセフォペラゾン組み合わせ製品」という用語には、Unasyn(登録商標)、Cefina−SB(登録商標)、Sulperazone(登録商標)、Sultamicillin(登録商標)及びBacperazone(登録商標)が含まれるが、これらに限定されるものではない。
最小発育阻止濃度(MIC)は、臨床・検査標準協会(CLSI)ガイドラインに従って、微量液体希釈法によって決定した。臨床・検査標準協会:好気性菌の抗菌薬感受性測定のための希釈検査法(第10版(2015))M07−A10。アシネトバクアター・バウマニ(n=60)臨床単離物のパネルに対するスルバクタムの活性を評価した。全てのクラス(A、B、C、及びD)の種々のβ−ラクタマーゼ類によって引き起こされたβ−ラクタム耐性単離物でパネルを濃縮した。MICは、CLSIガイドラインに従って決定し、単離物集団についてのMIC50及びMIC90値を算出した。インキュベーション後、目に見える成長を防いだ薬物の最低濃度をMICとして記録した。アッセイの性能は、ラボ品質の対照菌株と市販の対照化合物を使用して監視し、CLSIガイドラインに従ってMICスペクトルを定義した。
以下の化合物の各々のμg/mLでの最小発育阻止濃度(MIC)を示す:SUL=スルバクタム、UNA=Unasyn、アンピシリンとスルバクタムの2:1の組み合わせ、MEM=メロペネム、COL=コリスチン、LEVO=レボフロキサシン、GENT=ゲンタマイシン及びTET=テトラサイクリン。
実施例1に記載の方法に従って、スルバクタム+化合物1と、アンピシリン(Unasyn(登録商標))+化合物1と組み合わせたスルバクタムのMICを決定した。Unasyn(登録商標)の用量は、両方の組み合わせで投与したスルバクタムの総量が等しくなるように決定した。Unasyn(登録商標)の活性は、有効性ではスルバクタム成分にのみ依存し、アンピシリンは、アシネトバクアター・バウマニの治療の有効性に何の効果もないことを結果は示している。図2を参照されたい。
スルバクタム+化合物1の組み合わせのMICは、合計で825の最近の臨床アシネトバクアター・バウマニ単離物について、実施例1の手順に従って決定した。以下に示すように、組み合わせは、全ての単離物について4μg/mLのMIC90を有し、これは、予想されたブレイクポイントである。
表2:
アシネトバクアター・バウマニの一連の196の現代の臨床単離物に対する一般の抗生物質+化合物1の数の組み合わせについてのMIC90を決定した。表3に示すように、スルバクタム+化合物1は、CLSIブレイクポイントを下回るMIC90を有した、試験した唯一の組み合わせであった。スルバクタム+化合物1ブレイクポイントは、2のアンピシリン:スルバクタム(2:1)ブレイクポイントに基づいて予測されたことを留意されたい。
アシネトバクアター・バウマニ好中球減少性感染症モデル。アシネトバクアター・バウマニに対する活性を回復する化合物1の能力は、好中球減少性マウスの大腿及び肺感染症モデルで試験した。簡単に言えば、実験的な感染前にシクロホスファミドを腹腔内に4日間(150mg/kg体重)及び1日間(100mg/kg)注入することによって、CD−1マウスを好中球減少性にした。大腿モデルでは1×106CFUまたは肺モデルでは1×107CFUの標的接種を達成するために、対数中期培養物にマウスを感染させた。5匹の動物群の各々は、感染2時間後に開始して、スルバクタムのみまたは4:1の比率のスルバクタム+化合物1のいずれかを、q3hレジームで1日に8回の皮下注入を受けた。有効性は、治療開始24時間後に決定した。組織を除去し、重さを量り、均質にし、5%のヒツジ血液/50μg/mLゲンタマイシンを含有するトリプシン性大豆寒天プレート上にアリコートを載置し、37℃にて一晩インキュベートし、CFUを決定した。
類鼻疽の急性マウスモデルにおけるバークホルデリア・シュードマレイ臨床単離物(菌株K96243、スルバクタム:化合物1 MIC=1mg/L)に対するスルバクタム:化合物1のインビボ活性を評価した。致死チャレンジのK96243をBalb/cマウスに鼻腔内投与し、治療をチャレンジ4時間後に開始した後、6日間連続して投与した(表4)。ビヒクルのみを受けた動物は一般的に、試験の最初の3日以内に感染症で死亡する(図3)。生存者は、投与後39日間監視し、再発の可能性を評価し、並びに組織を採取して、病原菌の根絶を確認する。全ての試験について、ドキシサイクリン及びシプロフロキサシンは、正の有効性対照として作用した。この生物脅威病原菌に対するスルバクタム:化合物1の任意のPK/PD理解が無い場合には、初期の暴露−効果の関係に基づいて選択した用量は、MDRアシネトバクアター・バウマニに対する好中球減少大腿モデルで確立した。化合物1の暴露は、投与間隔の40%で2.5mg/Lの閾値濃度を上回る時間を標的化し、スルバクタム用量を漸増させて、組み合わせのMIC(1mg/L)を上回る時間が40〜60%の濃度範囲を達成した。図5に示すように、スルバクタム:化合物1による両方の治療群は、ドキシサイクリン及びシプロフロキサシンよりもバークホルデリア・シュードマレイK96243に対してより有効であり、ドキシサイクリン及びシプロフロキサシンがそれぞれ40%及び30%の生存率に対して60%の生存率を達成した。図5を参照されたい。
合計で59の最近の腸内細菌科臨床単離物についてのスルバクタム+化合物1の組み合わせのMICは、実施例1の手順に従って決定した。以下の個々の菌株ごとの表5、及び表6にまとめたように、全ての単離物についての組み合わせは、0.125μg/mL以下のMIC90を有する。図6を参照されたい。
アシネトバクアター・バウマニまたは緑膿菌の600の地理的に多様な菌株(2012年、2013年、及び2014年の各々から病原菌ごとに200菌株)を、イミペネム/シラスタチン(IPM)またはメロペネム(MER)のみ;4μg/mL化合物1の存在下でイミペネム/シラスタチンまたはメロペネム;または、化合物1及びスルバクタムが各々4μg/mLの組み合わせの存在下でイミペネム/シラスタチンまたはメロペネムへの感受性について試験した。表7に示すように、イミペネムまたはメロペネムの本来の抗菌活性は、化合物1をアシネトバクアター・バウマニ及び緑膿菌の両方に追加することによって著しく改善され、スルバクタム及び化合物1の両方をアシネトバクアター・バウマニに追加することによって著しく改善されたが、イミペネム/化合物1またはメロペネム/化合物1にスルバクタムを追加することで、緑膿菌に対する二重組み合わせの活性は変化しなかった。イミペネム/シラスタチン+化合物1の二重組み合わせは、両方の細菌種に対してメロペネム+化合物1よりも優れており、イミペネム/シラスタチン/スルバクタム/化合物1の四重組み合わせは、アシネトバクアター・バウマニ中のメロペネム/スルバクタム/化合物1のものよりも活性が測定可能な程度に優れている。アシネトバクアター・バウマニ及び緑膿菌の結果のグラフ表示については、それぞれ、図7及び8を参照されたい。
デザイン.臨床的に関連する濃度のイミペネムの有無による、OXA−94、OXA−23、及びAmpCを含有するアシネトバクアター・バウマニ単離物に対するスルバクタム:化合物1のインビトロ活性を評価した。定常状態の変動しない薬物濃度をインビトロ中空糸感染モデル(HFIM)でシミュレーションし、24時間の期間にわたってスルバクタム、化合物1、及びイミペネムへの暴露変化に対する細菌反応を評価した。1時間注入を介して化合物をシステムに投与し、2時間の半減期で等積的にクリアした。全ての組み合わせのQID(q6h)レジメンを評価した。全ての組み合わせのMICを表8にまとめる。10μg/mLの標的Cmaxを全てのスルバクタムレジメンで使用し、これは、4μg/mLのMICを上回る時間が50%のPK/PDエンドポイントを達成することと一致する(表xy)。10μg/mLの標的Cmaxを全てのイミペネムレジメンでも利用し、これは、4μg/mLのMICを上回る時間が50%のPK/PDエンドポイントを達成することと一致する。全ての場合において、いずれか1つの薬剤の暴露は、それ自身の有効性を達成するには不十分であり、個々のMICは、Cmax濃度を上回るかまたはCmax濃度に近い。化合物1は、各実験の用量範囲にわたって1μg/mLから8μg/mLに漸増した。おおよそ15mLの細菌(接種〜5×105CFU/mL)をセルロース中空糸カートリッジ中で増殖させ、化合物(複数)の用量投与を対数増殖期中に開始した。一連の試料を収集し、実際の薬物暴露及び総細菌負荷を決定した。24時間で、試料を薬物補充プレート上にも載置し、耐性菌集団を決定した。
全ゲノム配列決定によって決定された様々なβ−ラクタマーゼ含有量を有するアシネトバクアター・バウマニの20の多様な最近の菌株を、イミペネム、スルバクタム、化合物1、またはUnasyn(UNA)のみ、またはそれらの組み合わせに対する感受性について試験した。スルバクタム及びUnasynは、各組み合わせで同じ効果を有した。MICは、固有のβ−ラクタマーゼ含有量を有する20の菌株を用いて、実施例1の手順に従って決定した。それらは両方とも等しい効力を有し、Unasyn中のアンピシリンによって得られる利点はないため、組み合わせの活性に影響を及ぼすのは、Unasyn製品中のスルバクタムのみであることを結果(表10)は示している。
スルバクタム+化合物1+イミペネムの組み合わせのMICは、合計で59の最近の腸内細菌科臨床単離物(同じ単離物を実施例7に示す)について、実施例1の手順に従って決定した。以下の表12にまとめるように、組み合わせは、単離物に対して0.008μg/mLのMIC90を有する。
MICは、実施例1に記載の方法に従って、イミペネム+スルバクタム+以下のβ−ラクタマーゼ阻害剤の1つの組み合わせについて決定した:
Claims (9)
- 細菌感染症の治療に使用するための、β−ラクタマーゼ阻害剤:
- 細菌感染症の治療に使用するための、1つ以上の医薬的に許容される担体、及び/または希釈剤、及び任意にアンピシリンまたはセフォペラゾンをさらに含む、請求項1に記載の組み合わせを含む医薬。
- 前記β−ラクタマーゼ阻害剤が、ナトリウム塩の形態である、請求項1または2に記載の医薬。
- 前記細菌感染症が、腸内細菌科病原菌によって引き起こされる、請求項1〜3のいずれか1項に記載の医薬。
- 前記細菌感染症が、アシネトバクター属病原菌、緑膿菌、またはバークホルデリア属病原菌によって引き起こされる、請求項1〜3のいずれか1項に記載の医薬。
- 細菌感染症の治療に使用するための、β−ラクタマーゼ阻害剤:
- 前記細菌感染症が、腸内細菌科によって引き起こされる、請求項6に記載の医薬。
- 前記細菌感染症が、アシネトバクター属病原菌、緑膿菌、またはバークホルデリア属病原菌によって引き起こされる、請求項6に記載の医薬。
- 前記スルバクタムまたはその医薬的に許容される塩が、スルバクタム+アンピシリンまたはセフォペラゾン組み合わせ製品の一部である、請求項1〜8のいずれか1項に記載の医薬。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462080667P | 2014-11-17 | 2014-11-17 | |
US62/080,667 | 2014-11-17 | ||
PCT/US2015/061076 WO2016081452A1 (en) | 2014-11-17 | 2015-11-17 | Combination therapy for treatment of resistant bacterial infections |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2017533945A JP2017533945A (ja) | 2017-11-16 |
JP2017533945A5 JP2017533945A5 (ja) | 2018-12-20 |
JP6764862B2 true JP6764862B2 (ja) | 2020-10-07 |
Family
ID=54704148
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017526516A Active JP6764862B2 (ja) | 2014-11-17 | 2015-11-17 | 耐性細菌感染症の治療のための併用療法 |
Country Status (30)
Country | Link |
---|---|
US (2) | US9968593B2 (ja) |
EP (1) | EP3221313B1 (ja) |
JP (1) | JP6764862B2 (ja) |
KR (1) | KR102542392B1 (ja) |
CN (1) | CN107108624B (ja) |
AU (1) | AU2015350128B2 (ja) |
BR (1) | BR112017010132B1 (ja) |
CA (1) | CA2966632C (ja) |
CY (1) | CY1121384T1 (ja) |
DK (1) | DK3221313T3 (ja) |
EA (1) | EA033829B1 (ja) |
ES (1) | ES2717776T3 (ja) |
HK (1) | HK1244798B (ja) |
HR (1) | HRP20190580T1 (ja) |
HU (1) | HUE044061T2 (ja) |
IL (1) | IL251979B (ja) |
LT (1) | LT3221313T (ja) |
ME (1) | ME03357B (ja) |
MX (1) | MX2017006383A (ja) |
MY (1) | MY196240A (ja) |
PH (1) | PH12017500852A1 (ja) |
PL (1) | PL3221313T3 (ja) |
PT (1) | PT3221313T (ja) |
RS (1) | RS58429B1 (ja) |
SG (1) | SG11201703633TA (ja) |
SI (1) | SI3221313T1 (ja) |
TR (1) | TR201905233T4 (ja) |
TW (1) | TWI690317B (ja) |
WO (1) | WO2016081452A1 (ja) |
ZA (1) | ZA201703245B (ja) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102542392B1 (ko) | 2014-11-17 | 2023-06-09 | 엔타시스 테라퓨틱스 리미티드 | 내성 박테리아 감염의 치료를 위한 배합물 치료제 |
WO2017203266A1 (en) * | 2016-05-25 | 2017-11-30 | Entasis Therapeutics Limited | Combination therapy for treatment of resistant bacterial infections |
KR102667828B1 (ko) | 2016-09-16 | 2024-05-20 | 엔타시스 테라퓨틱스 리미티드 | 베타-락타마제 억제제 화합물 |
EP3301094A1 (en) * | 2016-09-30 | 2018-04-04 | Mutabilis | Heterocyclic compounds and their use in preventing or treating bacterial infections |
EA037916B1 (ru) * | 2017-02-08 | 2021-06-07 | Энтасис Терапеутикс Лимитед | Соединения-ингибиторы бета-лактамаз |
MX2019013291A (es) | 2017-05-08 | 2020-01-15 | Entasis Therapeutics Inc | Compuestos y metodos para tratar infecciones bacterianas. |
CN109422765B (zh) * | 2017-09-05 | 2020-08-28 | 香港理工大学深圳研究院 | C类β-内酰胺酶抑制剂及其制备方法和应用 |
PL3765055T3 (pl) * | 2018-03-13 | 2023-11-27 | Sepsia Therapeutics, S.L. | Peptydy wiążące bakterie do leczenia chorób zakaźnych i powiązanych procesów zapalnych |
US11905286B2 (en) | 2018-08-09 | 2024-02-20 | Antabio Sas | Diazabicyclooctanones as inhibitors of serine beta-lactamases |
CN111658642A (zh) * | 2019-03-05 | 2020-09-15 | 广州新创忆药物临床研究有限公司 | 一种治疗耐碳青霉烯类抗生素鲍曼不动杆菌感染的组合物 |
TWI715397B (zh) * | 2019-12-31 | 2021-01-01 | 高雄榮民總醫院 | 根據領先標準將同儕數據繪製為圖表的方法、電腦程式產品及電腦可讀取媒體 |
CN115335054A (zh) * | 2020-04-02 | 2022-11-11 | 葛兰素史克知识产权发展有限公司 | 用吉泊达星治疗淋病奈瑟氏菌的方案 |
JP2024504342A (ja) * | 2021-01-20 | 2024-01-31 | エンタシス・セラピューティックス・リミテッド | 固定用量抗生物質組成物 |
WO2023206580A1 (en) * | 2022-04-29 | 2023-11-02 | Entasis Therapeutics Limited | Durlobactam crystalline forms |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU699465B2 (en) | 1993-12-29 | 1998-12-03 | Pfizer Inc. | Diazabicyclic neurokinin antagonists |
FR2812635B1 (fr) | 2000-08-01 | 2002-10-11 | Aventis Pharma Sa | Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens |
FR2825705B1 (fr) * | 2001-06-08 | 2005-05-20 | Aventis Pharma Sa | Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens |
FR2835186B1 (fr) | 2002-01-28 | 2006-10-20 | Aventis Pharma Sa | Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases |
FR2848210B1 (fr) * | 2002-12-06 | 2007-10-19 | Aventis Pharma Sa | Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens et inhibiteurs de beta-lactamases |
US7439253B2 (en) | 2002-12-06 | 2008-10-21 | Novexel | Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors |
FR2914923B1 (fr) | 2007-04-12 | 2013-06-14 | Novexel | Nouveaux composes heterocycliques azotes,leur preparation et leur utilisation comme medicaments antibacteriens. |
ES2433744T3 (es) * | 2008-01-18 | 2013-12-12 | Merck Sharp & Dohme Corp. | Inhibidores de beta-lactamasas |
FR2930553B1 (fr) | 2008-04-29 | 2010-05-21 | Novexel | Composes azabicycliques, leur preparation et leur utilisation comme medicaments, notamment inhibiteurs de beta-lactamases |
EP2135959A1 (en) | 2008-06-19 | 2009-12-23 | Novexel | Use of (1R,2S,5R) 1,6-Diazabicyclo [3,2,1]octane-2-carboxamide, 7-oxo-6-(sulfooxy)-, monosodium salt as a diagnostic reagent for detecting serine beta-lactamases |
FR2936798B1 (fr) | 2008-10-03 | 2012-09-28 | Novexel | Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens. |
FR2936951B1 (fr) * | 2008-10-10 | 2010-12-03 | Novexel | Nouvelles combinaisons de composes heterocycliques azotes antibacteriens avec d'autres composes antibacteriens et leur utilisation comme medicaments |
FR2937034B1 (fr) | 2008-10-10 | 2012-11-23 | Novexel | Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens |
FR2951171A1 (fr) | 2009-10-09 | 2011-04-15 | Novexel | Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation |
BR112013032711A2 (pt) | 2011-07-26 | 2017-01-17 | Wockhardt Ltd | composições farmacêuticas compreendendo sulbactam e inibidor de beta-lactamase |
CA2842779C (en) * | 2011-07-26 | 2016-04-19 | Wockhardt Limited | Pharmaceutical compositions comprising beta-lactam antibiotic, sulbactam and beta-lactamase inhibitor |
PT2748165T (pt) | 2011-08-27 | 2016-12-28 | Wockhardt Ltd | Derivados de 1,6-diazabiciclo[3,2,1]octano-7-ona e sua utilização no tratamento de infeções bacterianas |
EP2872510B1 (en) | 2011-08-30 | 2016-11-23 | Wockhardt Limited | 1,6-diazabicyclo[3,2,1]octan-7-one derivatives and their use in the treatment of bacterial infections |
BR112014003476A2 (pt) | 2011-09-13 | 2017-03-01 | Wockhardt Ltd | compostos contendo nitrogênio e seu uso |
US8796257B2 (en) | 2011-12-02 | 2014-08-05 | Naeja Pharmaceutical Inc. | Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors |
WO2013122888A2 (en) * | 2012-02-15 | 2013-08-22 | Rempex Pharmaceuticals, Inc. | Methods of treating bacterial infections |
RU2014143821A (ru) | 2012-03-30 | 2016-05-27 | Кьюбист Фармасьютикалз, Инк. | 1, 3, 4-ОКСАДИАЗОЛЬНЫЕ И 1, 3, 4-ТИАДИАЗОЛЬНЫЕ ИНГИБИТОРЫ β-ЛАКТАМАЗЫ |
US8969570B2 (en) | 2012-03-30 | 2015-03-03 | Cubist Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
SG11201406120SA (en) | 2012-03-30 | 2014-10-30 | Cubist Pharm Inc | ISOXAZOLE β-LACTAMASE INHIBITORS |
US8916709B2 (en) | 2012-03-30 | 2014-12-23 | Cubist Pharmaceuticals, Inc. | 1,2,4-oxadiazole and 1,2,4-thiadiazole β-lactamase inhibitors |
AR090539A1 (es) * | 2012-04-02 | 2014-11-19 | Astrazeneca Ab | COMPUESTOS INHIBIDORES DE b LACTAMASA |
PL2857401T3 (pl) | 2012-05-30 | 2020-02-28 | Meiji Seika Pharma Co., Ltd. | NOWY INHIBITOR ß–LAKTAMAZY I SPOSÓB JEGO WYTWARZANIA |
BR112015003592B1 (pt) | 2012-08-25 | 2020-04-14 | Wockhardt Ltd | derivados de 1,6-diazabiciclo[3,2,1]octan-7-ona e seu uso no tratamento de infecções bacterianas |
CN104768547A (zh) * | 2012-09-03 | 2015-07-08 | 沃克哈特有限公司 | 抗菌组合物 |
AU2014213795B2 (en) * | 2013-02-06 | 2016-10-13 | Pfizer Anti-Infectives Ab | Combination therapy for the treatment of nosocomial pneumonia |
WO2014141132A1 (en) * | 2013-03-14 | 2014-09-18 | Naeja Pharmaceutical Inc. | NEW HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND β-LACTAMASE INHIBITORS |
KR102542392B1 (ko) | 2014-11-17 | 2023-06-09 | 엔타시스 테라퓨틱스 리미티드 | 내성 박테리아 감염의 치료를 위한 배합물 치료제 |
-
2015
- 2015-11-17 KR KR1020177016295A patent/KR102542392B1/ko active IP Right Grant
- 2015-11-17 SI SI201530648T patent/SI3221313T1/sl unknown
- 2015-11-17 RS RS20190328A patent/RS58429B1/sr unknown
- 2015-11-17 CN CN201580062519.5A patent/CN107108624B/zh active Active
- 2015-11-17 CA CA2966632A patent/CA2966632C/en active Active
- 2015-11-17 LT LTEP15801091.8T patent/LT3221313T/lt unknown
- 2015-11-17 PT PT15801091T patent/PT3221313T/pt unknown
- 2015-11-17 ME MEP-2019-80A patent/ME03357B/me unknown
- 2015-11-17 WO PCT/US2015/061076 patent/WO2016081452A1/en active Application Filing
- 2015-11-17 DK DK15801091.8T patent/DK3221313T3/en active
- 2015-11-17 MY MYPI2017000670A patent/MY196240A/en unknown
- 2015-11-17 TW TW104137939A patent/TWI690317B/zh active
- 2015-11-17 PL PL15801091T patent/PL3221313T3/pl unknown
- 2015-11-17 BR BR112017010132-7A patent/BR112017010132B1/pt active IP Right Grant
- 2015-11-17 EP EP15801091.8A patent/EP3221313B1/en active Active
- 2015-11-17 SG SG11201703633TA patent/SG11201703633TA/en unknown
- 2015-11-17 US US15/527,091 patent/US9968593B2/en active Active
- 2015-11-17 HU HUE15801091A patent/HUE044061T2/hu unknown
- 2015-11-17 MX MX2017006383A patent/MX2017006383A/es active IP Right Grant
- 2015-11-17 EA EA201791069A patent/EA033829B1/ru unknown
- 2015-11-17 JP JP2017526516A patent/JP6764862B2/ja active Active
- 2015-11-17 AU AU2015350128A patent/AU2015350128B2/en active Active
- 2015-11-17 ES ES15801091T patent/ES2717776T3/es active Active
- 2015-11-17 TR TR2019/05233T patent/TR201905233T4/tr unknown
-
2017
- 2017-04-27 IL IL251979A patent/IL251979B/en active IP Right Grant
- 2017-05-08 PH PH12017500852A patent/PH12017500852A1/en unknown
- 2017-05-10 ZA ZA2017/03245A patent/ZA201703245B/en unknown
-
2018
- 2018-03-26 HK HK18104155.3A patent/HK1244798B/zh unknown
- 2018-04-09 US US15/947,959 patent/US10376499B2/en active Active
-
2019
- 2019-03-18 CY CY20191100315T patent/CY1121384T1/el unknown
- 2019-03-25 HR HRP20190580TT patent/HRP20190580T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6764862B2 (ja) | 耐性細菌感染症の治療のための併用療法 | |
US9744160B2 (en) | Pharmaceutical compositions comprising sulbactam and beta-lactamase inhibitor | |
WO2017203266A1 (en) | Combination therapy for treatment of resistant bacterial infections | |
RU2593363C2 (ru) | Композиции, включающие антибактериальное средство и тазобактам | |
US9814754B2 (en) | Combinations with a backbone-cyclized peptide | |
CN110402139A (zh) | 治疗细菌感染的方法 | |
US9789097B2 (en) | Pharmaceutical compositions comprising antibacterial agents | |
US20140066517A1 (en) | Use of calixarenes associated with an antibotic in the treatment of bacterial infections | |
US20170000775A1 (en) | Pharmaceutical compositions comprising antibacterial agents | |
US20170065566A1 (en) | Pharmaceutical combinations comprising antibacterial agents | |
US20160287571A1 (en) | Pharmaceutical compositions comprising antibacterial agents | |
US20170151221A1 (en) | Pharmaceutical compositions comprising cefepime or sulbactam | |
US20170027917A1 (en) | Pharmaceutical compositions comprising antibacterial agents | |
WO2018193368A1 (en) | Antibacterial compositions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181109 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20181109 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20191023 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200121 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20200121 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200219 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200518 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200911 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200914 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6764862 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |